Cargando…

Allopurinol to reduce cardiovascular morbidity and mortality: A systematic review and meta-analysis

AIMS: To compare the effectiveness of allopurinol with no treatment or placebo for the prevention of cardiovascular events in hyperuricemic patients. METHODS AND RESULTS: Pubmed, Web of Science and Cochrane library were searched from inception until July 2020. Randomized controlled trials (RCT) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Pol, Karel H., Wever, Kimberley E., Verbakel, Mariette, Visseren, Frank L. J., Cornel, Jan H., Rongen, Gerard A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638940/ https://www.ncbi.nlm.nih.gov/pubmed/34855873 http://dx.doi.org/10.1371/journal.pone.0260844

Ejemplares similares

Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government
por: van der Pol, Karel H., et al.
Publicado: (2023)

Screen-detected abnormal ankle brachial index: A risk indicator for future cardiovascular morbidity and mortality in patients with manifest cardiovascular disease
por: Jagt, Vivianne L., et al.
Publicado: (2022)

Efficacy of Allopurinol in Cardiovascular Diseases: A Systematic Review and Meta-Analysis
por: Ullah, Waqas, et al.
Publicado: (2020)

Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
por: Guan, Xudong, et al.
Publicado: (2022)

Impact of allopurinol use on urate concentration and cardiovascular outcome
por: Wei, Li, et al.
Publicado: (2011)

Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity or Mortality? No
por: Kassem, Sameer A., et al.
Publicado: (2009)

Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout
por: Kang, Eun Ha, et al.
Publicado: (2021)

Cardiovascular risk associated with allopurinol or benzbromarone treatment in patients with gout
por: Eun, Yeonghee, et al.
Publicado: (2022)

Targeting aspirin resistance with nutraceuticals: a possible strategy for reducing cardiovascular morbidity and mortality
por: DiNicolantonio, James J, et al.
Publicado: (2017)

Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes
por: Bianchi, Cristina, et al.
Publicado: (2009)

Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
por: Gao, Linggen, et al.
Publicado: (2021)

Allopurinol reduces antigen-specific and polyclonal activation of human T cells
por: Pérez-Mazliah, Damián, et al.
Publicado: (2012)

Allopurinol induced erythroderma
por: Sharma, Geeta, et al.
Publicado: (2013)

Allopurinol: Sorrow to the marrow
por: Raaju, UR, et al.
Publicado: (2020)

Allopurinol hypersensitivity syndrome
por: Yaseen, Wid, et al.
Publicado: (2023)

Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes
por: Singh, Jasvinder A., et al.
Publicado: (2017)

Ischemic Preconditioning in the Animal Kidney, a Systematic Review and Meta-Analysis
por: Wever, Kimberley E., et al.
Publicado: (2012)

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials
por: de Jong, Marit, et al.
Publicado: (2017)

Extracellular vesicle markers in relation to obesity and metabolic complications in patients with manifest cardiovascular disease
por: Kranendonk, Mariëtte EG, et al.
Publicado: (2014)

The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease
por: Bots, Sophie H., et al.
Publicado: (2016)

Cardiovascular Safety of Febuxostat and Allopurinol in Hyperuricemic Patients With or Without Gout: A Network Meta-Analysis
por: Zhang, Shengzhao, et al.
Publicado: (2021)

Comment on: Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
por: Deng, Jian‐Hao, et al.
Publicado: (2022)

Allopurinol Lowers Serum Urate but Does Not Reduce Oxidative Stress in CKD
por: Sun, Mingyao, et al.
Publicado: (2022)

Mediation analysis of the relationship between type 2 diabetes and cardiovascular events and all‐cause mortality: Findings from the SMART cohort
por: Sharif, Shahnam, et al.
Publicado: (2019)

Reducing Sodium Consumption in Mexico: A Strategy to Decrease the Morbidity and Mortality of Cardiovascular Diseases
por: Campos-Nonato, Ismael, et al.
Publicado: (2022)

Allopurinol-induced DRESS syndrome
por: Yaylacı, Selcuk, et al.
Publicado: (2012)

Transient hypofibrinogenemia due to allopurinol
por: Yin, ZhiQiang, et al.
Publicado: (2014)

Diannexin Protects against Renal Ischemia Reperfusion Injury and Targets Phosphatidylserines in Ischemic Tissue
por: Wever, Kimberley E., et al.
Publicado: (2011)

Reply to comment on “Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis”
por: Gao, Linggen, et al.
Publicado: (2022)

Allopurinol for prevention of progression of kidney disease with hyperuricemia
por: Pai, B. H. Santhosh, et al.
Publicado: (2013)

Risk of Cardiovascular Morbidity and Mortality in Relation to Temperature
por: Mathes, Robert, et al.
Publicado: (2013)

Anger frequency and risk of cardiovascular morbidity and mortality
por: Titova, Olga E, et al.
Publicado: (2022)

Influenza Vaccination to Reduce Cardiovascular Morbidity and Mortality in Patients With COVID-19: JACC State-of-the-Art Review
por: Behrouzi, Bahar, et al.
Publicado: (2020)

Hyperuricaemia, gout and allopurinol in the CKD Queensland registry
por: Jeyaruban, A., et al.
Publicado: (2021)

The relation between urinary sodium and potassium excretion and risk of cardiovascular events and mortality in patients with cardiovascular disease
por: Groenland, Eline H., et al.
Publicado: (2022)

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol
por: Pawar, Ajinkya, et al.
Publicado: (2021)

Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014–2017
por: Weisshaar, Stefan, et al.
Publicado: (2022)

Attenuating the Variability of Lipids Is Beneficial for the Hypertension Management to Reduce the Cardiovascular Morbidity and Mortality in Older Adults
por: Dong, Yuanli, et al.
Publicado: (2021)

Editorial: Reducing cardiovascular disease mortality and morbidity: implementing cost-effective and sustainable preventive interventions
por: Mendis, Shanthi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rlor3f74li7p1iph36r1rn3ibo